Frontiers in Clinical Drug Research-Anti Infectives

Volume 1



DOI: 10.2174/97816080585491140101
eISBN: 978-1-60805-854-9, 2014
ISBN: 978-1-60805-855-6
ISSN: 2452-3208 (Print)
ISSN: 2352-3212 (Online)

Indexed in: EBSCO.

Frontiers in Clinical Drug Research – Anti Infectives is an eBook series that b...[view complete introduction]
US $
Buy Personal eBook
Order Library eBook
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

The Potential of Bacteriophage Lysins in the Treatment of Gram- Positive Bacteria Including Multidrug Resistant Bacteria

- Pp. 308-337 (30)

Raymond Schuch, Vincent A. Fischetti, Hoonmo L. Koo and David B. Huang


Almost two million Americans per year develop hospital-acquired infections, resulting in 99,000 deaths, the vast majority of which are due to antibiotic-resistant pathogens. Because of the pressing public concern over the emergence and global spread of MDR Gram-positive bacteria, as well as the serious and life threatening nature of these diseases and the limitations of current available antibiotics, global efforts are now focused on the development of novel and alternative antibacterial. One very promising new class of antimicrobial agents includes members of a widespread family of bacteriophage-encoded, bacterial cell wall-hydrolytic enzymes, or lysins. Lysins represent a new class of antibacterial agents against Gram-positive bacteria including multidrug-resistant bacteria, with a mechanism of action distinct from antibiotics. In this review, we will describe the nature of phage lysins, how they are distinguished from antibiotics, and how they may be applied to human medicine. Finally, we will discuss the hurdles to developing a new antimicrobial class and bringing it from the lab bench to the market.

Purchase Chapter  Book Details


Webmaster Contact: Copyright © 2019 Bentham Science